PDCD1 and Thrombocytopenia: We found that carrilizumab appeared in all treatment regimens with RCCEP, the treatment regimens of the above irAEs were mostly ICIs-targeted combination therapy and the type of ICIs was mainly PD-1, and bevacizumab was often seen in the treatment regimens of thrombocytopenia and hypertension.